Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer

TAS-102 is recommended as salvage-line therapy for metastatic colorectal cancer (mCRC), but practical predictors for its efficacy are lacking. In a single-institutional retrospective study of 33 patients treated with TAS-102, we investigated the predictive value of the pretreatment neutrophil-to-lym...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-08, Vol.39 (8), p.4343-4350
Main Authors: Matsuda, Akihisa, Yamada, Takeshi, Matsumoto, Satoshi, Sakurazawa, Nobuyuki, Kawano, Youichi, Shinozuka, Eriko, Sekiguchi, Kumiko, Suzuki, Hideyuki, Yoshida, Hiroshi
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Colorectal cancer
Colorectal carcinoma
Lymphocytes
Metastases
Metastasis
Monocytes
Neutrophils
Oncology
Salvage
Survival
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:TAS-102 is recommended as salvage-line therapy for metastatic colorectal cancer (mCRC), but practical predictors for its efficacy are lacking. In a single-institutional retrospective study of 33 patients treated with TAS-102, we investigated the predictive value of the pretreatment neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), and lymphocyte-monocyte (LMR) ratios for progression-free (PFS) and overall (OS) survival. Predictive ability using cut-offs of the median value (3.14) and 5 for NLR were compared. In univariate analysis, Eastern Cooperative Oncology Group performance score, NLR, and PLR were negatively significantly associated with PFS and OS. The number of treatment lines was negatively associated with PFS. The NLR cut-off of 5 was superior to the median value. Multivariate analyses showed a significant prognostic impact for NLR at cut-off 5 (hazard ratio(HR)=6.26, p=0.02 for PFS; HR=6.97, p=0.07 for OS). The pretreatment NLR is a prognostic biomarker for patients with mCRC who receive TAS-102 treatment.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13602